Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, ...

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

In the dim basement of a Salt Lake City pharmacy, hundreds of amber-colored plastic pill bottles sit stacked in rows, one man ...

On today's episode of Wealth, host Allie Canal speaks to a variety of Wall Street experts watching the markets, while tying ...

"Our biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of $200 million each in FY25," Biocon Group Chairperson Kiran Mazumdar-Shaw said in a ...

Seoul: Celltrion, a leading South Korean biopharmaceutical company, on Thursday said its business will remain largely ...

Taken together, the reports stand as an indictment of the entire programmatic ecosystem. Critics say the unsuitable ...

Bengaluru: Biocon, an Indian biopharmaceutical company, has reported a more than twofold increase in its fourth-quarter ...

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

Moving on to AVT04, our biosimilar to Stelara, we continue to build on the strong launch of this biosimilar under the UZPRUVO brand with STADA in Europe. In Europe, we were the first to market ...

SEOUL, May 15 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will ...